

PATENT

ATTORNEY DOCKET: 63024.000002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/667,966 Confirmation No.: 7892  
Applicant : Dong XIE et al.  
Filed : September 23, 2003  
Title : PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV  
INFECTION  
TC/Art Unit : 1645  
Examiner: : Not yet assigned  
  
Docket No. : 63024.000002  
Customer No. : 21967

**MAIL STOP AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants submit attached Form PTO-SB/08A (modified) for consideration and request the references cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

Applicants also enclose herewith a copy of the International Search Report for International Application No. PCT/US03/29815. The relevance of any of the documents cited in the Search Report as asserted by the Searching Authority is indicated on the enclosed copy of the Search Report.

Applicants respectfully point out that the submission of the listed references in this Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made by Applicants.

For the convenience of the Examiner in considering the cited references, a copy of each of the cited references is enclosed with this communication. In considering the cited references, it may be noted by the Examiner that certain of the references may contain markings,

underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited references. Any such markings were either present on the copies of the cited references obtained by the associated individuals, or were made thereon during the study of the references by the associated individuals.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action on the merits. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.


In the event any variance exists between the amount enclosed and the Patent Office charges, please charge or credit any difference to the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: November 24, 2004

By:

  
Robert C. Lampe, III  
Registration No. 51,914


Hunton & Williams LLP  
Intellectual Property Department  
1900 K Street, N.W.  
Suite 1200  
Washington, DC 20006  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/667,966
Filing Date	September 23, 2003
First Named Inventor	Dong XIE et al.
Art Unit	1645
Examiner Name	Not yet assigned



Sheet	1	of	2	Attorney Docket Number	63024.000002
-------	---	----	---	------------------------	--------------

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US- 3,719,667	03-06-1973	GUTOWSKI	
	2.	US- 3,840,556	10-08-1974	KUKOLJA	
	3.	US- 5,612,034	03-18-1997	POULETTY et al.	
	4.	US- 5,840,697	11-24-1998	BLONDELLE et al.	
	5.	US- 6,268,479 B1	07-31-2001	STERN et al.	
	6.	US- 6,281,331 B1	08-28-2001	KANG et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
	7.	PCT	WO 00/69902	11-23-2000	BRIDON et al.		<input type="checkbox"/>	<input type="checkbox"/>
	8.	PCT	WO 00/70665	11-23-2000	BRIDON et al.		<input type="checkbox"/>	<input type="checkbox"/>
	9.	PCT	WO 00/69911	11-23-2000	BRIDON et al.		<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

<b>Application Number</b>	<b>10/667,966</b>
<b>Filing Date</b>	<b>September 23, 2003</b>
<b>First Named Inventor</b>	<b>Dong XIE et al.</b>
<b>Art Unit</b>	<b>1645</b>
<b>Examiner Name</b>	<b>Not yet assigned</b>

<b>Sheet</b>	<b>2</b>	<b>of</b>	<b>2</b>	<b>Attorney Docket Number</b>	<b>63024.000002</b>
--------------	----------	-----------	----------	-------------------------------	---------------------

**OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	10.	T.W. GREEN, "Protection for the Carboxyl Group," Chapter 5, Protective Groups in Organic Synthesis, published by John Wiley & Sons, New York, USA, 1981, pp. 152-192.	<input type="checkbox"/>	<input type="checkbox"/>
	11.	CREAMER et al., " $\alpha$ -Helix-Forming Propensities in Peptides and Proteins," PROTEINS: Structure, Function, and Genetics 19:85-97 (1994), Wiley-Liss, Inc.	<input type="checkbox"/>	<input type="checkbox"/>
	12.	CHAN et al., "Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target," Proc. Natl. Acad. Sci. USA, vol. 95, pp. 15613-15617, December 1998, The National Academy of Sciences	<input type="checkbox"/>	<input type="checkbox"/>
	13.	MALASHKEVICH et al., "Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: Conserved helical interactions underlie the broad inhibitory activity of gp41 peptides," Proc. Natl. Acad. Sci. USA, vol. 95, pp 9134-9139, August 1998, The National Academy of Sciences	<input type="checkbox"/>	<input type="checkbox"/>
	14.	WILD et al., "Peptides corresponding to a predictive $\alpha$ -helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection," Proc. Natl. Acad. Sci. USA, vol. 91, pp. 9770-9774, October 1994, The National Academy of Sciences	<input type="checkbox"/>	<input type="checkbox"/>
	15.	STEHLE et al., "The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats," Anti-Cancer Drugs, 1997, vol. 8, pp. 677-685, Rapid Science Publishers	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.